Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study
about
Brainstem Glioma in AdultsDIPG in Children - What Can We Learn from the Past?Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and TreatmentRegorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy ModelsPermeability imaging in pediatric brain tumors.Opportunities and challenges for successful use of bevacizumab in pediatrics.Adult brainstem gliomasDrug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report.Bevacizumab for acute neurologic deterioration in patients with glioblastoma.Advances in the management of paediatric high-grade glioma.Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort.A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.Children's Oncology Group's 2013 blueprint for research: central nervous system tumors.Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters.Management of diffuse pontine gliomas in children: recent developments.The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.Brainstem glioma: a review.A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.Management of high-grade gliomas in the pediatric patient: Past, present, and future.Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine gliomaChallenging issues in pediatric oncologyDose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumorsAutocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.Diffuse intrinsic pontine glioma: poised for progress.Advances in paediatric cancer treatmentThe VEGF pathway in cancer and disease: responses, resistance, and the path forward.Immunotherapy in pediatric malignancies: current status and future perspectivesNeurotoxicity of biologically targeted agents in pediatric cancer trialsBiologically targeted therapeutics in pediatric brain tumors.Bevacizumab for the treatment of glioblastoma.The rationale for targeted therapies in medulloblastoma.Characterization of the blood brain barrier in pediatric central nervous system neoplasms.Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experienceEfficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
P2860
Q26739232-71B44482-EE0A-4B90-BF44-1CEC1CA4A4C2Q26777843-618161A1-EDC1-4025-A1BF-5F28C0830E6CQ26785952-409C9829-503C-4766-851D-A9757B1A280EQ27345024-5EAF88ED-A75B-43AF-9BA0-01CEE9F66BA9Q30392559-F5D91AF0-94BA-4ABA-B14F-18AD55D2CF24Q30454883-1E98ABB0-974D-45F2-A228-AA4C32D3B561Q30457821-A1DA8BF3-8716-487C-9E79-BC9DC6316303Q30616602-2D5BB87E-9540-4B02-ACB8-F5BBEAD35535Q30679553-F1D787AF-6530-4532-A937-FF9494EC868DQ30838127-BA680AF7-87F9-4786-81A3-80AEAD7BAAF4Q30870633-92ABA3C1-E715-426E-AB9D-4424BEEDA932Q33416917-284404EC-E420-4849-9B2D-B00DF91A84C1Q33428049-F07BC310-5BDD-4368-8E8D-D124526D12FAQ33438641-738C3A95-1034-43BA-9A1E-D6B2DC559C83Q34285237-A95D0395-F3C7-47BB-819E-9A5025F2D26AQ34286305-B325CEDE-9D00-4F0B-A482-030F2B512DF4Q34347540-6650E508-88AB-4D93-9F82-CA81BDEDC688Q34468816-2CC048BF-D5B3-4133-A253-9D22E12A80B2Q34628180-97B00AA0-5DD1-43C2-9113-CF9DC71188FBQ34872658-0A04EE93-07CF-4179-BC17-3DAAB5D4B6A2Q35021664-57C00175-4DA4-428D-B471-8B849E7B2940Q35090526-EEE6E452-F5BD-44BF-8A63-47F3E11D4EAFQ35206259-BBBB0EA3-E8B0-4E03-A60A-B07CFA79ACC6Q35230772-4E3CCACD-24F9-4CE7-866D-C5B447532303Q35602419-E86C2900-FF8B-4E40-BFE1-2B08E965DC06Q35667216-0E3C0762-6E4F-4774-B7B9-8481236F0D44Q35826030-A0425003-9C60-4A1A-885F-60A4E8163695Q36031619-4B693196-ABD9-486F-B1C7-5C9C3D7A7F2BQ36344746-1BFA3C28-C5AB-4D20-B0AC-309F0C7C93F7Q36492719-65CCF05B-D551-4D37-9693-89133B17886DQ36508630-CC98556E-D884-4A8B-AFF9-9538A0A898F8Q36526512-6C5FAD1D-5125-4DC6-8DD6-1D0FF43D7516Q36691818-0B6C7C48-4F8B-4F57-8CFA-AE52495B3114Q36766221-CCC9DBAD-0C6C-42FD-9555-23D106C3A127Q36844744-EFFDCB86-C8E4-4031-AB40-FE9807AD0EECQ36929502-4D03F34A-9291-4F0E-AC96-FAD09BD4B012Q37409736-6D86D5C6-A0AD-4137-AE37-B8FA8C183A81Q37462324-ECA2AE10-7B13-4169-B775-15DEB88A83C9Q37484213-3705D522-9DC8-4A5E-A28F-F765AEDE8BE7Q37492128-C1E2C544-D89D-4F59-85FD-DB56EC84343D
P2860
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study
@ast
Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study
@en
type
label
Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study
@ast
Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study
@en
prefLabel
Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study
@ast
Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study
@en
P2093
P2860
P356
P1476
Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study
@en
P2093
Arzu Onar-Thomas
Brian N Rood
James M Boyett
Larry E Kun
Richard J Gilbertson
Roger J Packer
Sridhar Vajapeyam
Susan N Chi
Tina Young Poussaint
P2860
P304
P356
10.1200/JCO.2009.26.8789
P407
P577
2010-05-17T00:00:00Z